Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21563189 | 0.81 | CSNK2A1 (0.36) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 | |
| SCHEMBL25829653 | 0.81 | TRPA1 (0.38) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 | |
| SCHEMBL18544267 | 0.80 | TRPA1 (0.38) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 | |
| SCHEMBL21598409 | 0.78 | HPGD (0.40) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 | |
| SCHEMBL20687487 | 0.78 | TRPA1 (0.36) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30990063 | 0.72 | CSNK2A1 (0.40) | CSNK2A1HIPK2HPGDSMN1; SMN2LRRK2 | |
| SCHEMBL3572514 | 0.72 | CSNK2A1 (0.40) | CSNK2A1HIPK2HPGDSMN1; SMN2LRRK2 | |
| SCHEMBL26694677 | 0.71 | TRPA1 (0.32) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27243791 | 0.69 | TRPA1 (0.52) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 | |
| SCHEMBL22034054 | 0.69 | HPGD (0.37) | TRPA1CSNK2A1HIPK2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4011886-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| WO-2021023154-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| CN-112074520-A | Tetracycloheteroaryl compounds | 阿斯利康(瑞典)有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TRPA1 3780/4885CSNK2A1 1076/4885HIPK2 4009/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | TRPA1 2775/4885CSNK2A1 2860/4885HIPK2 867/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | TRPA1 3780/4885CSNK2A1 1076/4885HIPK2 4009/4885 |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | CCNI, MCL1, MKI67 | TRPA1 4641/4885CSNK2A1 411/4885HIPK2 3835/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | TRPA1 2775/4885CSNK2A1 2860/4885HIPK2 867/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | TRPA1 4084/4885CSNK2A1 500/4885HIPK2 1363/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | TRPA1 2775/4885CSNK2A1 2860/4885HIPK2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.